#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=Tom Jefferson ( epidemiologist )
1-1	0-3	Tom	person[1]	new[1]	appos	1-4[0_1]
1-2	4-13	Jefferson	person[1]	new[1]	_	_
1-3	14-15	(	_	_	_	_
1-4	16-30	epidemiologist	person	giv	coref	2-1[3_0]
1-5	31-32	)	_	_	_	_

#Text=Tom Jefferson is a British epidemiologist , based in Rome , Italy , [ 1 ] who works for the Cochrane Collaboration .
2-1	33-36	Tom	person[3]	giv[3]	coref	2-4[4_3]
2-2	37-46	Jefferson	person[3]	giv[3]	_	_
2-3	47-49	is	_	_	_	_
2-4	50-51	a	person[4]	giv[4]	coref	3-1[0_4]
2-5	52-59	British	person[4]	giv[4]	_	_
2-6	60-74	epidemiologist	person[4]	giv[4]	_	_
2-7	75-76	,	person[4]	giv[4]	_	_
2-8	77-82	based	person[4]	giv[4]	_	_
2-9	83-85	in	person[4]	giv[4]	_	_
2-10	86-90	Rome	person[4]|place[5]	giv[4]|new[5]	_	_
2-11	91-92	,	person[4]|place[5]	giv[4]|new[5]	_	_
2-12	93-98	Italy	person[4]|place[5]	giv[4]|new[5]	_	_
2-13	99-100	,	person[4]	giv[4]	_	_
2-14	101-102	[	person[4]	giv[4]	_	_
2-15	103-104	1	person[4]|abstract	giv[4]|new	coref	16-37
2-16	105-106	]	person[4]	giv[4]	_	_
2-17	107-110	who	person[4]	giv[4]	_	_
2-18	111-116	works	person[4]	giv[4]	_	_
2-19	117-120	for	person[4]	giv[4]	_	_
2-20	121-124	the	person[4]|abstract[8]	giv[4]|new[8]	coref	3-9[14_8]
2-21	125-133	Cochrane	person[4]|organization|abstract[8]	giv[4]|new|new[8]	coref	3-9
2-22	134-147	Collaboration	person[4]|abstract[8]	giv[4]|new[8]	_	_
2-23	148-149	.	_	_	_	_

#Text=Jefferson is an author and editor of the Cochrane Collaboration 's acute respiratory infections group , as well as part of four other Cochrane groups . [ 2 ]
3-1	150-159	Jefferson	person	giv	coref	3-3[10_0]
3-2	160-162	is	_	_	_	_
3-3	163-165	an	person[10]|person[11]	giv[10]|giv[11]	coref|ana	3-3[11_10]|4-1[0_11]
3-4	166-172	author	person[10]|person[11]	giv[10]|giv[11]	_	_
3-5	173-176	and	person[11]	giv[11]	_	_
3-6	177-183	editor	person[11]|person[12]	giv[11]|new[12]	_	_
3-7	184-186	of	person[11]|person[12]	giv[11]|new[12]	_	_
3-8	187-190	the	person[11]|person[12]|abstract[16]	giv[11]|new[12]|new[16]	_	_
3-9	191-199	Cochrane	person[11]|person[12]|organization|abstract[14]|abstract[16]	giv[11]|new[12]|giv|giv[14]|new[16]	_	_
3-10	200-213	Collaboration	person[11]|person[12]|abstract[14]|abstract[16]	giv[11]|new[12]|giv[14]|new[16]	_	_
3-11	214-216	's	person[11]|person[12]|abstract[14]|abstract[16]	giv[11]|new[12]|giv[14]|new[16]	_	_
3-12	217-222	acute	person[11]|person[12]|abstract[15]|abstract[16]	giv[11]|new[12]|new[15]|new[16]	_	_
3-13	223-234	respiratory	person[11]|person[12]|abstract[15]|abstract[16]	giv[11]|new[12]|new[15]|new[16]	_	_
3-14	235-245	infections	person[11]|person[12]|abstract[15]|abstract[16]	giv[11]|new[12]|new[15]|new[16]	_	_
3-15	246-251	group	person[11]|person[12]|abstract[16]	giv[11]|new[12]|new[16]	_	_
3-16	252-253	,	person[11]	giv[11]	_	_
3-17	254-256	as	person[11]	giv[11]	_	_
3-18	257-261	well	person[11]	giv[11]	_	_
3-19	262-264	as	person[11]	giv[11]	_	_
3-20	265-269	part	person[11]	giv[11]	_	_
3-21	270-272	of	person[11]	giv[11]	_	_
3-22	273-277	four	person[11]|organization[18]	giv[11]|new[18]	_	_
3-23	278-283	other	person[11]|organization[18]	giv[11]|new[18]	_	_
3-24	284-292	Cochrane	person[11]|person|organization[18]	giv[11]|new|new[18]	coref	6-5
3-25	293-299	groups	person[11]|organization[18]	giv[11]|new[18]	_	_
3-26	300-301	.	_	_	_	_
3-27	302-303	[	_	_	_	_
3-28	304-305	2	abstract	new	coref	4-17
3-29	306-307	]	_	_	_	_

#Text=He is also an advisor to the Italian National Agency for Regional Health Services . [ 2 ]
4-1	308-310	He	person	giv	coref	4-4[21_0]
4-2	311-313	is	_	_	_	_
4-3	314-318	also	_	_	_	_
4-4	319-321	an	person[21]	giv[21]	coref	5-3[0_21]
4-5	322-329	advisor	person[21]	giv[21]	_	_
4-6	330-332	to	person[21]	giv[21]	_	_
4-7	333-336	the	person[21]|organization[22]	giv[21]|new[22]	coref	13-13[80_22]
4-8	337-344	Italian	person[21]|organization[22]	giv[21]|new[22]	_	_
4-9	345-353	National	person[21]|organization[22]	giv[21]|new[22]	_	_
4-10	354-360	Agency	person[21]|organization[22]	giv[21]|new[22]	_	_
4-11	361-364	for	person[21]|organization[22]	giv[21]|new[22]	_	_
4-12	365-373	Regional	person[21]|organization[22]|organization[23]	giv[21]|new[22]|new[23]	coref	12-2[65_23]
4-13	374-380	Health	person[21]|organization[22]|organization[23]	giv[21]|new[22]|new[23]	_	_
4-14	381-389	Services	person[21]|organization[22]|organization[23]	giv[21]|new[22]|new[23]	_	_
4-15	390-391	.	_	_	_	_
4-16	392-393	[	_	_	_	_
4-17	394-395	2	abstract	giv	_	_
4-18	396-397	]	_	_	_	_

#Text=In 1999 Jefferson was one of the founding members of the Brighton Collaboration along with Harald Heijbel , Ulrich Heininger , and Elisabeth Loupi . [ 3 ]
5-1	398-400	In	_	_	_	_
5-2	401-405	1999	time	new	_	_
5-3	406-415	Jefferson	person	giv	ana	6-1
5-4	416-419	was	_	_	_	_
5-5	420-423	one	person[27]	new[27]	_	_
5-6	424-426	of	person[27]	new[27]	_	_
5-7	427-430	the	person[27]|person[28]	new[27]|new[28]	_	_
5-8	431-439	founding	person[27]|person[28]	new[27]|new[28]	_	_
5-9	440-447	members	person[27]|person[28]	new[27]|new[28]	_	_
5-10	448-450	of	person[27]|person[28]	new[27]|new[28]	_	_
5-11	451-454	the	person[27]|person[28]|abstract[30]	new[27]|new[28]|new[30]	_	_
5-12	455-463	Brighton	person[27]|person[28]|person|abstract[30]	new[27]|new[28]|new|new[30]	_	_
5-13	464-477	Collaboration	person[27]|person[28]|abstract[30]	new[27]|new[28]|new[30]	_	_
5-14	478-483	along	person[27]|person[28]|person[31]	new[27]|new[28]|new[31]	_	_
5-15	484-488	with	person[27]|person[28]|person[31]	new[27]|new[28]|new[31]	_	_
5-16	489-495	Harald	person[27]|person[28]|person[31]	new[27]|new[28]|new[31]	_	_
5-17	496-503	Heijbel	person[27]|person[28]|person[31]	new[27]|new[28]|new[31]	_	_
5-18	504-505	,	person[27]|person[28]	new[27]|new[28]	_	_
5-19	506-512	Ulrich	person[27]|person[28]|person[32]	new[27]|new[28]|new[32]	_	_
5-20	513-522	Heininger	person[27]|person[28]|person[32]	new[27]|new[28]|new[32]	_	_
5-21	523-524	,	person[27]|person[28]	new[27]|new[28]	_	_
5-22	525-528	and	person[27]|person[28]	new[27]|new[28]	_	_
5-23	529-538	Elisabeth	person[27]|person[28]|person[33]	new[27]|new[28]|new[33]	_	_
5-24	539-544	Loupi	person[27]|person[28]|person[33]	new[27]|new[28]|new[33]	_	_
5-25	545-546	.	_	_	_	_
5-26	547-548	[	_	_	_	_
5-27	549-550	3	abstract	new	_	_
5-28	551-552	]	_	_	_	_

#Text=He has worked on Cochrane reviews examining the effectiveness of the anti-viral oseltamivir and the influenza vaccine . [ 4 ]
6-1	553-555	He	person	giv	coref	9-1
6-2	556-559	has	_	_	_	_
6-3	560-566	worked	_	_	_	_
6-4	567-569	on	_	_	_	_
6-5	570-578	Cochrane	person|abstract[37]	giv|new[37]	coref	14-11
6-6	579-586	reviews	abstract[37]	new[37]	_	_
6-7	587-596	examining	abstract[37]	new[37]	_	_
6-8	597-600	the	abstract[37]|abstract[38]	new[37]|new[38]	_	_
6-9	601-614	effectiveness	abstract[37]|abstract[38]	new[37]|new[38]	_	_
6-10	615-617	of	abstract[37]|abstract[38]	new[37]|new[38]	_	_
6-11	618-621	the	abstract[37]|abstract[38]|substance[39]	new[37]|new[38]|new[39]	coref	9-17[0_39]
6-12	622-632	anti-viral	abstract[37]|abstract[38]|substance[39]	new[37]|new[38]|new[39]	_	_
6-13	633-644	oseltamivir	abstract[37]|abstract[38]|substance[39]	new[37]|new[38]|new[39]	_	_
6-14	645-648	and	abstract[37]|abstract[38]	new[37]|new[38]	_	_
6-15	649-652	the	abstract[37]|abstract[38]|substance[41]	new[37]|new[38]|new[41]	coref	16-30[0_41]
6-16	653-662	influenza	abstract[37]|abstract[38]|abstract|substance[41]	new[37]|new[38]|new|new[41]	coref	14-29
6-17	663-670	vaccine	abstract[37]|abstract[38]|substance[41]	new[37]|new[38]|new[41]	_	_
6-18	671-672	.	_	_	_	_
6-19	673-674	[	_	_	_	_
6-20	675-676	4	abstract	new	coref	9-20
6-21	677-678	]	_	_	_	_

#Text=Notable work
7-1	679-686	Notable	abstract[43]	new[43]	_	_
7-2	687-691	work	abstract[43]	new[43]	_	_

#Text=In 2009
8-1	692-694	In	_	_	_	_
8-2	695-699	2009	time	new	coref	12-22

#Text=Jefferson was hired by the governments of Britain and Australia to update a systematic review of oseltamivir . [ 4 ]
9-1	700-709	Jefferson	person	giv	ana	10-2
9-2	710-713	was	_	_	_	_
9-3	714-719	hired	_	_	_	_
9-4	720-722	by	_	_	_	_
9-5	723-726	the	organization[46]	new[46]	_	_
9-6	727-738	governments	organization[46]	new[46]	_	_
9-7	739-741	of	organization[46]	new[46]	_	_
9-8	742-749	Britain	organization[46]|place	new[46]|new	_	_
9-9	750-753	and	organization[46]	new[46]	_	_
9-10	754-763	Australia	organization[46]|place	new[46]|new	_	_
9-11	764-766	to	_	_	_	_
9-12	767-773	update	_	_	_	_
9-13	774-775	a	abstract[49]	new[49]	_	_
9-14	776-786	systematic	abstract[49]	new[49]	_	_
9-15	787-793	review	abstract[49]	new[49]	_	_
9-16	794-796	of	abstract[49]	new[49]	_	_
9-17	797-808	oseltamivir	abstract[49]|substance	new[49]|giv	coref	14-19
9-18	809-810	.	_	_	_	_
9-19	811-812	[	_	_	_	_
9-20	813-814	4	abstract	giv	coref	10-17
9-21	815-816	]	_	_	_	_

#Text=Initially he had a great deal of trouble getting results of the original trials . [ 4 ]
10-1	817-826	Initially	_	_	_	_
10-2	827-829	he	person	giv	coref	14-4
10-3	830-833	had	_	_	_	_
10-4	834-835	a	abstract[53]	new[53]	_	_
10-5	836-841	great	abstract[53]	new[53]	_	_
10-6	842-846	deal	abstract[53]	new[53]	_	_
10-7	847-849	of	abstract[53]	new[53]	_	_
10-8	850-857	trouble	abstract[53]	new[53]	_	_
10-9	858-865	getting	abstract[53]	new[53]	_	_
10-10	866-873	results	abstract[53]|abstract[54]	new[53]|new[54]	_	_
10-11	874-876	of	abstract[53]|abstract[54]	new[53]|new[54]	_	_
10-12	877-880	the	abstract[53]|abstract[54]|event[55]	new[53]|new[54]|new[55]	coref	11-5[0_55]
10-13	881-889	original	abstract[53]|abstract[54]|event[55]	new[53]|new[54]|new[55]	_	_
10-14	890-896	trials	abstract[53]|abstract[54]|event[55]	new[53]|new[54]|new[55]	_	_
10-15	897-898	.	_	_	_	_
10-16	899-900	[	_	_	_	_
10-17	901-902	4	abstract	giv	ana	11-12
10-18	903-904	]	_	_	_	_

#Text=Previous researchers had published trials without seeing the underlying data and it appeared that some of the published papers used ghost writers . [ 4 ]
11-1	905-913	Previous	person[57]	new[57]	ana	11-15[61_57]
11-2	914-925	researchers	person[57]	new[57]	_	_
11-3	926-929	had	_	_	_	_
11-4	930-939	published	_	_	_	_
11-5	940-946	trials	event	giv	coref	12-9[67_0]
11-6	947-954	without	_	_	_	_
11-7	955-961	seeing	_	_	_	_
11-8	962-965	the	abstract[59]	new[59]	coref	12-14[0_59]
11-9	966-976	underlying	abstract[59]	new[59]	_	_
11-10	977-981	data	abstract[59]	new[59]	_	_
11-11	982-985	and	_	_	_	_
11-12	986-988	it	abstract	giv	coref	11-25
11-13	989-997	appeared	_	_	_	_
11-14	998-1002	that	_	_	_	_
11-15	1003-1007	some	person[61]	giv[61]	ana	12-19[0_61]
11-16	1008-1010	of	person[61]	giv[61]	_	_
11-17	1011-1014	the	person[61]|abstract[62]	giv[61]|new[62]	_	_
11-18	1015-1024	published	person[61]|abstract[62]	giv[61]|new[62]	_	_
11-19	1025-1031	papers	person[61]|abstract[62]	giv[61]|new[62]	_	_
11-20	1032-1036	used	_	_	_	_
11-21	1037-1042	ghost	person[63]	new[63]	_	_
11-22	1043-1050	writers	person[63]	new[63]	_	_
11-23	1051-1052	.	_	_	_	_
11-24	1053-1054	[	_	_	_	_
11-25	1055-1056	4	abstract	giv	coref	12-32
11-26	1057-1058	]	_	_	_	_

#Text=As the company , Roche , that did the trials refused to provide data for independent analysis , their conclusions in 2009 were that benefits could not be shown . [ 4 ]
12-1	1059-1061	As	_	_	_	_
12-2	1062-1065	the	organization[65]	giv[65]	_	_
12-3	1066-1073	company	organization[65]	giv[65]	_	_
12-4	1074-1075	,	_	_	_	_
12-5	1076-1081	Roche	person	new	coref	13-18
12-6	1082-1083	,	_	_	_	_
12-7	1084-1088	that	_	_	_	_
12-8	1089-1092	did	_	_	_	_
12-9	1093-1096	the	event[67]	giv[67]	coref	19-6[141_67]
12-10	1097-1103	trials	event[67]	giv[67]	_	_
12-11	1104-1111	refused	_	_	_	_
12-12	1112-1114	to	_	_	_	_
12-13	1115-1122	provide	_	_	_	_
12-14	1123-1127	data	abstract	giv	coref	13-11
12-15	1128-1131	for	_	_	_	_
12-16	1132-1143	independent	abstract[69]	new[69]	_	_
12-17	1144-1152	analysis	abstract[69]	new[69]	_	_
12-18	1153-1154	,	_	_	_	_
12-19	1155-1160	their	person|abstract[71]	giv|new[71]	coref	16-29[115_0]
12-20	1161-1172	conclusions	abstract[71]	new[71]	_	_
12-21	1173-1175	in	abstract[71]	new[71]	_	_
12-22	1176-1180	2009	abstract[71]|time	new[71]|giv	coref	32-23
12-23	1181-1185	were	_	_	_	_
12-24	1186-1190	that	_	_	_	_
12-25	1191-1199	benefits	abstract	new	_	_
12-26	1200-1205	could	_	_	_	_
12-27	1206-1209	not	_	_	_	_
12-28	1210-1212	be	_	_	_	_
12-29	1213-1218	shown	_	_	_	_
12-30	1219-1220	.	_	_	_	_
12-31	1221-1222	[	_	_	_	_
12-32	1223-1224	4	abstract	giv	coref	13-27
12-33	1225-1226	]	_	_	_	_

#Text=In 2011 Jefferson 's team was provided 22,000 pages of data from the European Medicines Agency and Roche eventually provided 3,000 pages of data . [ 4 ]
13-1	1227-1229	In	_	_	_	_
13-2	1230-1234	2011	time	new	_	_
13-3	1235-1244	Jefferson	person[76]	new[76]	_	_
13-4	1245-1247	's	person[76]	new[76]	_	_
13-5	1248-1252	team	person[76]	new[76]	_	_
13-6	1253-1256	was	_	_	_	_
13-7	1257-1265	provided	_	_	_	_
13-8	1266-1272	22,000	object[77]	new[77]	_	_
13-9	1273-1278	pages	object[77]	new[77]	_	_
13-10	1279-1281	of	object[77]	new[77]	_	_
13-11	1282-1286	data	object[77]|abstract	new[77]|giv	coref	13-24
13-12	1287-1291	from	_	_	_	_
13-13	1292-1295	the	organization[80]	giv[80]	_	_
13-14	1296-1304	European	organization[80]	giv[80]	_	_
13-15	1305-1314	Medicines	organization|organization[80]	new|giv[80]	_	_
13-16	1315-1321	Agency	organization[80]	giv[80]	_	_
13-17	1322-1325	and	_	_	_	_
13-18	1326-1331	Roche	person	giv	_	_
13-19	1332-1342	eventually	_	_	_	_
13-20	1343-1351	provided	_	_	_	_
13-21	1352-1357	3,000	object[82]	new[82]	_	_
13-22	1358-1363	pages	object[82]	new[82]	_	_
13-23	1364-1366	of	object[82]	new[82]	_	_
13-24	1367-1371	data	object[82]|abstract	new[82]|giv	coref	14-14[90_0]
13-25	1372-1373	.	_	_	_	_
13-26	1374-1375	[	_	_	_	_
13-27	1376-1377	4	abstract	giv	_	_
13-28	1378-1379	]	_	_	_	_

#Text=In 2012 , Jefferson was the lead author of another Cochrane review of this data which concluded that oseltamivir did not reduce the number of hospitalizations caused by influenza .
14-1	1380-1382	In	_	_	_	_
14-2	1383-1387	2012	time	new	_	_
14-3	1388-1389	,	_	_	_	_
14-4	1390-1399	Jefferson	person	giv	coref	14-6[87_0]
14-5	1400-1403	was	_	_	_	_
14-6	1404-1407	the	person[87]	giv[87]	coref	15-1[0_87]
14-7	1408-1412	lead	person[87]	giv[87]	_	_
14-8	1413-1419	author	person[87]	giv[87]	_	_
14-9	1420-1422	of	person[87]	giv[87]	_	_
14-10	1423-1430	another	person[87]|abstract[89]	giv[87]|new[89]	coref	15-4[96_89]
14-11	1431-1439	Cochrane	person[87]|person|abstract[89]	giv[87]|giv|new[89]	_	_
14-12	1440-1446	review	person[87]|abstract[89]	giv[87]|new[89]	_	_
14-13	1447-1449	of	person[87]|abstract[89]	giv[87]|new[89]	_	_
14-14	1450-1454	this	person[87]|abstract[89]|abstract[90]	giv[87]|new[89]|giv[90]	_	_
14-15	1455-1459	data	person[87]|abstract[89]|abstract[90]	giv[87]|new[89]|giv[90]	_	_
14-16	1460-1465	which	person[87]|abstract[89]	giv[87]|new[89]	_	_
14-17	1466-1475	concluded	person[87]|abstract[89]	giv[87]|new[89]	_	_
14-18	1476-1480	that	person[87]|abstract[89]	giv[87]|new[89]	_	_
14-19	1481-1492	oseltamivir	person[87]|abstract[89]|substance	giv[87]|new[89]|giv	coref	15-11
14-20	1493-1496	did	person[87]|abstract[89]	giv[87]|new[89]	_	_
14-21	1497-1500	not	person[87]|abstract[89]	giv[87]|new[89]	_	_
14-22	1501-1507	reduce	person[87]|abstract[89]	giv[87]|new[89]	_	_
14-23	1508-1511	the	person[87]|abstract[89]|abstract[92]	giv[87]|new[89]|new[92]	_	_
14-24	1512-1518	number	person[87]|abstract[89]|abstract[92]	giv[87]|new[89]|new[92]	_	_
14-25	1519-1521	of	person[87]|abstract[89]|abstract[92]	giv[87]|new[89]|new[92]	_	_
14-26	1522-1538	hospitalizations	person[87]|abstract[89]|abstract[92]|abstract[93]	giv[87]|new[89]|new[92]|new[93]	_	_
14-27	1539-1545	caused	person[87]|abstract[89]|abstract[92]|abstract[93]	giv[87]|new[89]|new[92]|new[93]	_	_
14-28	1546-1548	by	person[87]|abstract[89]|abstract[92]|abstract[93]	giv[87]|new[89]|new[92]|new[93]	_	_
14-29	1549-1558	influenza	person[87]|abstract[89]|abstract[92]|abstract[93]|abstract	giv[87]|new[89]|new[92]|new[93]|giv	coref	16-7
14-30	1559-1560	.	_	_	_	_

#Text=Jefferson said that this review also found no evidence that oseltamivir stopped complications from the disease . [ 5 ]
15-1	1561-1570	Jefferson	person	giv	ana	16-1
15-2	1571-1575	said	_	_	_	_
15-3	1576-1580	that	_	_	_	_
15-4	1581-1585	this	abstract[96]	giv[96]	coref	23-4[166_96]
15-5	1586-1592	review	abstract[96]	giv[96]	_	_
15-6	1593-1597	also	_	_	_	_
15-7	1598-1603	found	_	_	_	_
15-8	1604-1606	no	abstract[97]	new[97]	coref	17-10[119_97]
15-9	1607-1615	evidence	abstract[97]	new[97]	_	_
15-10	1616-1620	that	abstract[97]	new[97]	_	_
15-11	1621-1632	oseltamivir	abstract[97]|substance	new[97]|giv	_	_
15-12	1633-1640	stopped	abstract[97]	new[97]	_	_
15-13	1641-1654	complications	abstract[97]|abstract[99]	new[97]|new[99]	_	_
15-14	1655-1659	from	abstract[97]|abstract[99]	new[97]|new[99]	_	_
15-15	1660-1663	the	abstract[97]|abstract[99]|abstract[100]	new[97]|new[99]|new[100]	_	_
15-16	1664-1671	disease	abstract[97]|abstract[99]|abstract[100]	new[97]|new[99]|new[100]	_	_
15-17	1672-1673	.	_	_	_	_
15-18	1674-1675	[	_	_	_	_
15-19	1676-1677	5	abstract	new	_	_
15-20	1678-1679	]	_	_	_	_

#Text=His views about the effectiveness of influenza vaccines and his outspokenness about them are also controversial ; at a 2007 meeting on pandemic preparedness he was shunned by other vaccine researchers and ate alone . [ 1 ]
16-1	1680-1683	His	person|abstract[103]	giv|new[103]	ana|coref	16-10|20-1[149_103]
16-2	1684-1689	views	abstract[103]	new[103]	_	_
16-3	1690-1695	about	abstract[103]	new[103]	_	_
16-4	1696-1699	the	abstract[103]|abstract[104]|abstract[105]	new[103]|new[104]|new[105]	ana	16-13[0_105]
16-5	1700-1713	effectiveness	abstract[103]|abstract[104]|abstract[105]	new[103]|new[104]|new[105]	_	_
16-6	1714-1716	of	abstract[103]|abstract[104]|abstract[105]	new[103]|new[104]|new[105]	_	_
16-7	1717-1726	influenza	abstract[103]|abstract[104]|abstract[105]|abstract|substance[107]	new[103]|new[104]|new[105]|giv|new[107]	coref|coref	17-15|17-15[121_107]
16-8	1727-1735	vaccines	abstract[103]|abstract[104]|abstract[105]|substance[107]	new[103]|new[104]|new[105]|new[107]	_	_
16-9	1736-1739	and	abstract[103]|abstract[105]	new[103]|new[105]	_	_
16-10	1740-1743	his	abstract[103]|abstract[105]|person	new[103]|new[105]|giv	ana	16-25
16-11	1744-1757	outspokenness	abstract[103]|abstract[105]	new[103]|new[105]	_	_
16-12	1758-1763	about	abstract[103]|abstract[105]	new[103]|new[105]	_	_
16-13	1764-1768	them	abstract[103]|abstract[105]|abstract	new[103]|new[105]|giv	_	_
16-14	1769-1772	are	_	_	_	_
16-15	1773-1777	also	_	_	_	_
16-16	1778-1791	controversial	_	_	_	_
16-17	1792-1793	;	_	_	_	_
16-18	1794-1796	at	_	_	_	_
16-19	1797-1798	a	event[110]	new[110]	_	_
16-20	1799-1803	2007	event[110]	new[110]	_	_
16-21	1804-1811	meeting	event[110]	new[110]	_	_
16-22	1812-1814	on	event[110]	new[110]	_	_
16-23	1815-1823	pandemic	event[110]|plant|abstract[112]	new[110]|new|new[112]	_	_
16-24	1824-1836	preparedness	event[110]|abstract[112]	new[110]|new[112]	_	_
16-25	1837-1839	he	person	giv	coref	17-4
16-26	1840-1843	was	_	_	_	_
16-27	1844-1851	shunned	_	_	_	_
16-28	1852-1854	by	_	_	_	_
16-29	1855-1860	other	person[115]	giv[115]	_	_
16-30	1861-1868	vaccine	substance|person[115]	giv|giv[115]	coref	18-17[131_0]
16-31	1869-1880	researchers	person[115]	giv[115]	_	_
16-32	1881-1884	and	_	_	_	_
16-33	1885-1888	ate	_	_	_	_
16-34	1889-1894	alone	_	_	_	_
16-35	1895-1896	.	_	_	_	_
16-36	1897-1898	[	_	_	_	_
16-37	1899-1900	1	abstract	giv	coref	18-26
16-38	1901-1902	]	_	_	_	_

#Text=Reviews led by Jefferson have concluded that there is insufficient evidence to show that influenza vaccines reduce mortality or infection rates . [ 6 ]
17-1	1903-1910	Reviews	event[117]	new[117]	_	_
17-2	1911-1914	led	event[117]	new[117]	_	_
17-3	1915-1917	by	event[117]	new[117]	_	_
17-4	1918-1927	Jefferson	event[117]|person	new[117]|giv	ana	18-1
17-5	1928-1932	have	_	_	_	_
17-6	1933-1942	concluded	_	_	_	_
17-7	1943-1947	that	_	_	_	_
17-8	1948-1953	there	_	_	_	_
17-9	1954-1956	is	_	_	_	_
17-10	1957-1969	insufficient	abstract[119]	giv[119]	_	_
17-11	1970-1978	evidence	abstract[119]	giv[119]	_	_
17-12	1979-1981	to	abstract[119]	giv[119]	_	_
17-13	1982-1986	show	abstract[119]	giv[119]	_	_
17-14	1987-1991	that	abstract[119]	giv[119]	_	_
17-15	1992-2001	influenza	abstract[119]|abstract|substance[121]	giv[119]|giv|giv[121]	coref|coref	18-18|18-31[136_121]
17-16	2002-2010	vaccines	abstract[119]|substance[121]	giv[119]|giv[121]	_	_
17-17	2011-2017	reduce	abstract[119]	giv[119]	_	_
17-18	2018-2027	mortality	abstract[119]|event	giv[119]|new	_	_
17-19	2028-2030	or	abstract[119]	giv[119]	_	_
17-20	2031-2040	infection	abstract[119]|abstract|abstract[124]	giv[119]|new|new[124]	coref	18-11[129_124]
17-21	2041-2046	rates	abstract[119]|abstract[124]	giv[119]|new[124]	_	_
17-22	2047-2048	.	_	_	_	_
17-23	2049-2050	[	_	_	_	_
17-24	2051-2052	6	abstract	new	coref	24-10
17-25	2053-2054	]	_	_	_	_

#Text=He has said that the studies claiming large reductions in mortality rates as a result of the influenza vaccine are " rubbish " , [ 1 ] and that " influenza vaccines are about marketing and not science " . [ 7 ]
18-1	2055-2057	He	person	giv	ana	19-1
18-2	2058-2061	has	_	_	_	_
18-3	2062-2066	said	_	_	_	_
18-4	2067-2071	that	_	_	_	_
18-5	2072-2075	the	abstract[127]	new[127]	coref	18-22[0_127]
18-6	2076-2083	studies	abstract[127]	new[127]	_	_
18-7	2084-2092	claiming	abstract[127]	new[127]	_	_
18-8	2093-2098	large	abstract[127]|abstract[128]	new[127]|new[128]	_	_
18-9	2099-2109	reductions	abstract[127]|abstract[128]	new[127]|new[128]	_	_
18-10	2110-2112	in	abstract[127]|abstract[128]	new[127]|new[128]	_	_
18-11	2113-2122	mortality	abstract[127]|abstract[128]|abstract[129]	new[127]|new[128]|giv[129]	_	_
18-12	2123-2128	rates	abstract[127]|abstract[128]|abstract[129]	new[127]|new[128]|giv[129]	_	_
18-13	2129-2131	as	abstract[127]	new[127]	_	_
18-14	2132-2133	a	abstract[127]	new[127]	_	_
18-15	2134-2140	result	abstract[127]	new[127]	_	_
18-16	2141-2143	of	abstract[127]	new[127]	_	_
18-17	2144-2147	the	abstract[127]|substance[131]	new[127]|giv[131]	_	_
18-18	2148-2157	influenza	abstract[127]|abstract|substance[131]	new[127]|giv|giv[131]	coref	18-31
18-19	2158-2165	vaccine	abstract[127]|substance[131]	new[127]|giv[131]	_	_
18-20	2166-2169	are	_	_	_	_
18-21	2170-2171	"	abstract[133]	giv[133]	coref	18-21[133_0]
18-22	2172-2179	rubbish	abstract|abstract[133]	giv|giv[133]	_	_
18-23	2180-2181	"	abstract[133]	giv[133]	_	_
18-24	2182-2183	,	abstract[133]	giv[133]	_	_
18-25	2184-2185	[	abstract[133]	giv[133]	_	_
18-26	2186-2187	1	abstract[133]|abstract	giv[133]|giv	coref	19-30
18-27	2188-2189	]	abstract[133]	giv[133]	_	_
18-28	2190-2193	and	abstract[133]	giv[133]	_	_
18-29	2194-2198	that	abstract[133]	giv[133]	_	_
18-30	2199-2200	"	abstract[133]	giv[133]	_	_
18-31	2201-2210	influenza	abstract[133]|abstract|substance[136]	giv[133]|giv|giv[136]	coref|coref	19-15[144_136]|33-3
18-32	2211-2219	vaccines	abstract[133]|substance[136]	giv[133]|giv[136]	_	_
18-33	2220-2223	are	abstract[133]	giv[133]	_	_
18-34	2224-2229	about	abstract[133]	giv[133]	_	_
18-35	2230-2239	marketing	abstract[133]|person	giv[133]|new	_	_
18-36	2240-2243	and	abstract[133]	giv[133]	_	_
18-37	2244-2247	not	abstract[133]	giv[133]	_	_
18-38	2248-2255	science	abstract[133]|abstract	giv[133]|new	_	_
18-39	2256-2257	"	abstract[133]	giv[133]	_	_
18-40	2258-2259	.	_	_	_	_
18-41	2260-2261	[	_	_	_	_
18-42	2262-2263	7	abstract	new	coref	34-8
18-43	2264-2265	]	_	_	_	_

#Text=He has called repeatedly for placebo-controlled randomized clinical trials to prove the efficacy of flu vaccines , a position that most in the field hold as unethical . [ 1 ]
19-1	2266-2268	He	person	giv	ana	20-1
19-2	2269-2272	has	_	_	_	_
19-3	2273-2279	called	_	_	_	_
19-4	2280-2290	repeatedly	_	_	_	_
19-5	2291-2294	for	_	_	_	_
19-6	2295-2313	placebo-controlled	event[141]	giv[141]	_	_
19-7	2314-2324	randomized	event[141]	giv[141]	_	_
19-8	2325-2333	clinical	event[141]	giv[141]	_	_
19-9	2334-2340	trials	event[141]	giv[141]	_	_
19-10	2341-2343	to	_	_	_	_
19-11	2344-2349	prove	_	_	_	_
19-12	2350-2353	the	abstract[142]	new[142]	appos	19-18[145_142]
19-13	2354-2362	efficacy	abstract[142]	new[142]	_	_
19-14	2363-2365	of	abstract[142]	new[142]	_	_
19-15	2366-2369	flu	abstract[142]|abstract|substance[144]	new[142]|new|giv[144]	coref|coref	20-4|20-4[151_144]
19-16	2370-2378	vaccines	abstract[142]|substance[144]	new[142]|giv[144]	_	_
19-17	2379-2380	,	_	_	_	_
19-18	2381-2382	a	abstract[145]	giv[145]	_	_
19-19	2383-2391	position	abstract[145]	giv[145]	_	_
19-20	2392-2396	that	abstract[145]	giv[145]	_	_
19-21	2397-2401	most	abstract[145]	giv[145]	_	_
19-22	2402-2404	in	abstract[145]	giv[145]	_	_
19-23	2405-2408	the	abstract[145]|abstract[146]	giv[145]|new[146]	_	_
19-24	2409-2414	field	abstract[145]|abstract[146]	giv[145]|new[146]	_	_
19-25	2415-2419	hold	abstract[145]	giv[145]	_	_
19-26	2420-2422	as	abstract[145]	giv[145]	_	_
19-27	2423-2432	unethical	abstract[145]	giv[145]	_	_
19-28	2433-2434	.	_	_	_	_
19-29	2435-2436	[	_	_	_	_
19-30	2437-2438	1	abstract	giv	coref	20-14
19-31	2439-2440	]	_	_	_	_

#Text=His views on flu vaccines are opposed by the medical establishment . [ 1 ]
20-1	2441-2444	His	person|abstract[149]	giv|giv[149]	coref	22-1[155_0]
20-2	2445-2450	views	abstract[149]	giv[149]	_	_
20-3	2451-2453	on	abstract[149]	giv[149]	_	_
20-4	2454-2457	flu	abstract[149]|abstract|substance[151]	giv[149]|giv|giv[151]	coref	33-2[198_151]
20-5	2458-2466	vaccines	abstract[149]|substance[151]	giv[149]|giv[151]	_	_
20-6	2467-2470	are	_	_	_	_
20-7	2471-2478	opposed	_	_	_	_
20-8	2479-2481	by	_	_	_	_
20-9	2482-2485	the	organization[152]	new[152]	_	_
20-10	2486-2493	medical	organization[152]	new[152]	_	_
20-11	2494-2507	establishment	organization[152]	new[152]	_	_
20-12	2508-2509	.	_	_	_	_
20-13	2510-2511	[	_	_	_	_
20-14	2512-2513	1	abstract	giv	_	_
20-15	2514-2515	]	_	_	_	_

#Text=Publications
21-1	2516-2528	Publications	organization	new	_	_

#Text=Jefferson , T ; Alderson , P ; Wager , E ; Davidoff , F ( 5 June 2002 ) .
22-1	2529-2538	Jefferson	person[155]|person[156]	giv[155]|giv[156]	coref|coref	22-1[156_155]|27-1[173_156]
22-2	2539-2540	,	person[155]|person[156]	giv[155]|giv[156]	_	_
22-3	2541-2542	T	person[155]|person[156]	giv[155]|giv[156]	_	_
22-4	2543-2544	;	person[156]	giv[156]	_	_
22-5	2545-2553	Alderson	person[156]|person[157]	giv[156]|new[157]	_	_
22-6	2554-2555	,	person[156]|person[157]	giv[156]|new[157]	_	_
22-7	2556-2557	P	person[156]|person[157]|person	giv[156]|new[157]|new	_	_
22-8	2558-2559	;	person[156]	giv[156]	_	_
22-9	2560-2565	Wager	person[156]|person[159]	giv[156]|new[159]	coref	27-5[174_159]
22-10	2566-2567	,	person[156]|person[159]	giv[156]|new[159]	_	_
22-11	2568-2569	E	person[156]|person[159]	giv[156]|new[159]	_	_
22-12	2570-2571	;	person[156]	giv[156]	_	_
22-13	2572-2580	Davidoff	person[156]|person[160]	giv[156]|new[160]	coref	27-9[175_160]
22-14	2581-2582	,	person[156]|person[160]	giv[156]|new[160]	_	_
22-15	2583-2584	F	person[156]|person[160]|person	giv[156]|new[160]|new	coref	27-11
22-16	2585-2586	(	person[156]|person[160]	giv[156]|new[160]	_	_
22-17	2587-2588	5	person[156]|person[160]	giv[156]|new[160]	_	_
22-18	2589-2593	June	person[156]|person[160]|time	giv[156]|new[160]|new	coref	27-14
22-19	2594-2598	2002	person[156]|person[160]|time	giv[156]|new[160]|new	coref	27-15
22-20	2599-2600	)	person[156]|person[160]	giv[156]|new[160]	_	_
22-21	2601-2602	.	_	_	_	_

#Text=" Effects of editorial peer review : a systematic review " .
23-1	2603-2604	"	_	_	_	_
23-2	2605-2612	Effects	abstract[164]	new[164]	_	_
23-3	2613-2615	of	abstract[164]	new[164]	_	_
23-4	2616-2625	editorial	abstract[164]|abstract[166]	new[164]|giv[166]	appos	23-8[167_166]
23-5	2626-2630	peer	abstract[164]|person|abstract[166]	new[164]|new|giv[166]	coref	28-7
23-6	2631-2637	review	abstract[164]|abstract[166]	new[164]|giv[166]	_	_
23-7	2638-2639	:	_	_	_	_
23-8	2640-2641	a	abstract[167]	giv[167]	coref	28-6[181_167]
23-9	2642-2652	systematic	abstract[167]	giv[167]	_	_
23-10	2653-2659	review	abstract[167]	giv[167]	_	_
23-11	2660-2661	"	_	_	_	_
23-12	2662-2663	.	_	_	_	_

#Text=JAMA . 287 ( 21 ) : 2784 – 6 .
24-1	2664-2668	JAMA	organization[168]	new[168]	coref	29-1[182_168]
24-2	2669-2670	.	organization[168]	new[168]	_	_
24-3	2671-2674	287	organization[168]	new[168]	_	_
24-4	2675-2676	(	organization[168]	new[168]	_	_
24-5	2677-2679	21	organization[168]|abstract	new[168]|new	coref	29-5
24-6	2680-2681	)	organization[168]	new[168]	_	_
24-7	2682-2683	:	organization[168]	new[168]	_	_
24-8	2684-2688	2784	organization[168]	new[168]	_	_
24-9	2689-2690	–	organization[168]	new[168]	_	_
24-10	2691-2692	6	organization[168]|abstract	new[168]|giv	_	_
24-11	2693-2694	.	_	_	_	_

#Text=doi : 10.1001/jama.287.21.2784 .
25-1	2695-2698	doi	abstract[171]	new[171]	coref	30-1[184_171]
25-2	2699-2700	:	abstract[171]	new[171]	_	_
25-3	2701-2725	10.1001/jama.287.21.2784	abstract[171]	new[171]	_	_
25-4	2726-2727	.	_	_	_	_

#Text=PMID 12038911 .
26-1	2728-2732	PMID	place[172]	new[172]	_	_
26-2	2733-2741	12038911	place[172]	new[172]	_	_
26-3	2742-2743	.	_	_	_	_

#Text=Jefferson , T ; Wager , E ; Davidoff , F ( 5 June 2002 ) .
27-1	2744-2753	Jefferson	person[173]	giv[173]	coref	32-1[186_173]
27-2	2754-2755	,	person[173]	giv[173]	_	_
27-3	2756-2757	T	person[173]	giv[173]	_	_
27-4	2758-2759	;	_	_	_	_
27-5	2760-2765	Wager	person[174]	giv[174]	_	_
27-6	2766-2767	,	person[174]	giv[174]	_	_
27-7	2768-2769	E	person[174]	giv[174]	_	_
27-8	2770-2771	;	_	_	_	_
27-9	2772-2780	Davidoff	person[175]	giv[175]	_	_
27-10	2781-2782	,	person[175]	giv[175]	_	_
27-11	2783-2784	F	person[175]|person	giv[175]|giv	_	_
27-12	2785-2786	(	person[175]	giv[175]	_	_
27-13	2787-2788	5	person[175]	giv[175]	_	_
27-14	2789-2793	June	person[175]|time	giv[175]|giv	_	_
27-15	2794-2798	2002	person[175]|time	giv[175]|giv	_	_
27-16	2799-2800	)	person[175]	giv[175]	_	_
27-17	2801-2802	.	_	_	_	_

#Text=" Measuring the quality of editorial peer review " .
28-1	2803-2804	"	_	_	_	_
28-2	2805-2814	Measuring	_	_	_	_
28-3	2815-2818	the	abstract[179]	new[179]	_	_
28-4	2819-2826	quality	abstract[179]	new[179]	_	_
28-5	2827-2829	of	abstract[179]	new[179]	_	_
28-6	2830-2839	editorial	abstract[179]|abstract[181]	new[179]|giv[181]	_	_
28-7	2840-2844	peer	abstract[179]|person|abstract[181]	new[179]|giv|giv[181]	_	_
28-8	2845-2851	review	abstract[179]|abstract[181]	new[179]|giv[181]	_	_
28-9	2852-2853	"	_	_	_	_
28-10	2854-2855	.	_	_	_	_

#Text=JAMA . 287 ( 21 ) : 2786 – 90 .
29-1	2856-2860	JAMA	organization[182]	giv[182]	_	_
29-2	2861-2862	.	organization[182]	giv[182]	_	_
29-3	2863-2866	287	organization[182]	giv[182]	_	_
29-4	2867-2868	(	organization[182]	giv[182]	_	_
29-5	2869-2871	21	organization[182]|abstract	giv[182]|giv	_	_
29-6	2872-2873	)	organization[182]	giv[182]	_	_
29-7	2874-2875	:	organization[182]	giv[182]	_	_
29-8	2876-2880	2786	organization[182]	giv[182]	_	_
29-9	2881-2882	–	organization[182]	giv[182]	_	_
29-10	2883-2885	90	organization[182]	giv[182]	_	_
29-11	2886-2887	.	_	_	_	_

#Text=doi : 10.1001/jama.287.21.2786 .
30-1	2888-2891	doi	abstract[184]	giv[184]	coref	35-1[205_184]
30-2	2892-2893	:	abstract[184]	giv[184]	_	_
30-3	2894-2918	10.1001/jama.287.21.2786	abstract[184]	giv[184]	_	_
30-4	2919-2920	.	_	_	_	_

#Text=PMID 12038912 .
31-1	2921-2925	PMID	place[185]	new[185]	_	_
31-2	2926-2934	12038912	place[185]	new[185]	_	_
31-3	2935-2936	.	_	_	_	_

#Text=Jefferson , T ; Di Pietrantonj , C ; Debalini , MG ; Rivetti , A ; Demicheli , V ( July 2009 ) .
32-1	2937-2946	Jefferson	person[186]	giv[186]	coref	37-1[207_186]
32-2	2947-2948	,	person[186]	giv[186]	_	_
32-3	2949-2950	T	person[186]	giv[186]	_	_
32-4	2951-2952	;	_	_	_	_
32-5	2953-2955	Di	person[187]	new[187]	_	_
32-6	2956-2967	Pietrantonj	person[187]	new[187]	_	_
32-7	2968-2969	,	person[187]	new[187]	_	_
32-8	2970-2971	C	person[187]|person	new[187]|new	_	_
32-9	2972-2973	;	_	_	_	_
32-10	2974-2982	Debalini	person[189]	new[189]	_	_
32-11	2983-2984	,	person[189]	new[189]	_	_
32-12	2985-2987	MG	person[189]|person	new[189]|new	_	_
32-13	2988-2989	;	_	_	_	_
32-14	2990-2997	Rivetti	person[191]	new[191]	coref	37-38[221_191]
32-15	2998-2999	,	person[191]	new[191]	_	_
32-16	3000-3001	A	person[191]|person	new[191]|new	coref	37-20[214_0]
32-17	3002-3003	;	person[191]	new[191]	_	_
32-18	3004-3013	Demicheli	person[191]|person[193]	new[191]|new[193]	_	_
32-19	3014-3015	,	person[191]|person[193]	new[191]|new[193]	_	_
32-20	3016-3017	V	person[191]|person[193]|person	new[191]|new[193]|new	_	_
32-21	3018-3019	(	person[191]	new[191]	_	_
32-22	3020-3024	July	person[191]|time[195]	new[191]|new[195]	_	_
32-23	3025-3029	2009	person[191]|time[195]|time	new[191]|new[195]|giv	coref	37-44
32-24	3030-3031	)	person[191]	new[191]	_	_
32-25	3032-3033	.	_	_	_	_

#Text=" Inactivated influenza vaccines : methods , policies , and politics " .
33-1	3034-3035	"	_	_	_	_
33-2	3036-3047	Inactivated	substance[198]	giv[198]	_	_
33-3	3048-3057	influenza	abstract|substance[198]	giv|giv[198]	_	_
33-4	3058-3066	vaccines	substance[198]	giv[198]	_	_
33-5	3067-3068	:	_	_	_	_
33-6	3069-3076	methods	abstract	new	_	_
33-7	3077-3078	,	_	_	_	_
33-8	3079-3087	policies	abstract	new	_	_
33-9	3088-3089	,	_	_	_	_
33-10	3090-3093	and	_	_	_	_
33-11	3094-3102	politics	abstract	new	_	_
33-12	3103-3104	"	_	_	_	_
33-13	3105-3106	.	_	_	_	_

#Text=Journal of Clinical Epidemiology . 62 ( 7 ) : 677 – 86 .
34-1	3107-3114	Journal	organization[202]	new[202]	_	_
34-2	3115-3117	of	organization[202]	new[202]	_	_
34-3	3118-3126	Clinical	organization[202]|abstract[203]	new[202]|new[203]	_	_
34-4	3127-3139	Epidemiology	organization[202]|abstract[203]	new[202]|new[203]	_	_
34-5	3140-3141	.	organization[202]	new[202]	_	_
34-6	3142-3144	62	organization[202]	new[202]	_	_
34-7	3145-3146	(	organization[202]	new[202]	_	_
34-8	3147-3148	7	organization[202]|abstract	new[202]|giv	_	_
34-9	3149-3150	)	organization[202]	new[202]	_	_
34-10	3151-3152	:	organization[202]	new[202]	_	_
34-11	3153-3156	677	organization[202]	new[202]	_	_
34-12	3157-3158	–	organization[202]	new[202]	_	_
34-13	3159-3161	86	organization[202]	new[202]	_	_
34-14	3162-3163	.	_	_	_	_

#Text=doi : 10.1016/j . jclinepi.2008.07.001 .
35-1	3164-3167	doi	abstract[205]	giv[205]	coref	40-1[232_205]
35-2	3168-3169	:	abstract[205]	giv[205]	_	_
35-3	3170-3179	10.1016/j	abstract[205]	giv[205]	_	_
35-4	3180-3181	.	abstract[205]	giv[205]	_	_
35-5	3182-3202	jclinepi.2008.07.001	abstract[205]	giv[205]	_	_
35-6	3203-3204	.	_	_	_	_

#Text=PMID 19124222 .
36-1	3205-3209	PMID	place[206]	new[206]	_	_
36-2	3210-3218	19124222	place[206]	new[206]	_	_
36-3	3219-3220	.	_	_	_	_

#Text=Jefferson , T. ; Del Mar , C. ; Dooley , L. ; Ferroni , E. ; Al-Ansary , L. A ; Bawazeer , G. A ; van Driel , M. L ; Foxlee , R. ; Rivetti , A. ( 22 September 2009 ) .
37-1	3221-3230	Jefferson	person[207]	giv[207]	coref	42-13[239_207]
37-2	3231-3232	,	person[207]	giv[207]	_	_
37-3	3233-3235	T.	person[207]	giv[207]	_	_
37-4	3236-3237	;	_	_	_	_
37-5	3238-3241	Del	person[208]	new[208]	_	_
37-6	3242-3245	Mar	person[208]	new[208]	_	_
37-7	3246-3247	,	person[208]	new[208]	_	_
37-8	3248-3250	C.	person[208]|person	new[208]|new	_	_
37-9	3251-3252	;	_	_	_	_
37-10	3253-3259	Dooley	person[210]	new[210]	_	_
37-11	3260-3261	,	person[210]	new[210]	_	_
37-12	3262-3264	L.	person[210]	new[210]	_	_
37-13	3265-3266	;	_	_	_	_
37-14	3267-3274	Ferroni	person[211]	new[211]	_	_
37-15	3275-3276	,	person[211]	new[211]	_	_
37-16	3277-3279	E.	person[211]|person	new[211]|new	_	_
37-17	3280-3281	;	_	_	_	_
37-18	3282-3291	Al-Ansary	person[213]	new[213]	_	_
37-19	3292-3293	,	person[213]	new[213]	_	_
37-20	3294-3296	L.	person[213]|person[214]	new[213]|giv[214]	coref	37-25[216_214]
37-21	3297-3298	A	person[213]|person[214]	new[213]|giv[214]	_	_
37-22	3299-3300	;	_	_	_	_
37-23	3301-3309	Bawazeer	person[215]	new[215]	_	_
37-24	3310-3311	,	person[215]	new[215]	_	_
37-25	3312-3314	G.	person[215]|person[216]	new[215]|giv[216]	_	_
37-26	3315-3316	A	person[215]|person[216]	new[215]|giv[216]	_	_
37-27	3317-3318	;	_	_	_	_
37-28	3319-3322	van	object[217]	new[217]	coref	42-35[248_217]
37-29	3323-3328	Driel	object[217]	new[217]	_	_
37-30	3329-3330	,	object[217]	new[217]	_	_
37-31	3331-3333	M.	object[217]|person	new[217]|new	_	_
37-32	3334-3335	L	object[217]	new[217]	_	_
37-33	3336-3337	;	_	_	_	_
37-34	3338-3344	Foxlee	person[219]	new[219]	_	_
37-35	3345-3346	,	person[219]	new[219]	_	_
37-36	3347-3349	R.	person[219]|person	new[219]|new	_	_
37-37	3350-3351	;	person[219]	new[219]	_	_
37-38	3352-3359	Rivetti	person[219]|person[221]	new[219]|giv[221]	_	_
37-39	3360-3361	,	person[219]|person[221]	new[219]|giv[221]	_	_
37-40	3362-3364	A.	person[219]|person[221]|person	new[219]|giv[221]|new	_	_
37-41	3365-3366	(	person[219]	new[219]	_	_
37-42	3367-3369	22	person[219]|time[223]	new[219]|new[223]	_	_
37-43	3370-3379	September	person[219]|time[223]|time	new[219]|new[223]|new	_	_
37-44	3380-3384	2009	person[219]|time[223]|time	new[219]|new[223]|giv	_	_
37-45	3385-3386	)	person[219]	new[219]	_	_
37-46	3387-3388	.	_	_	_	_

#Text=" Physical interventions to interrupt or reduce the spread of respiratory viruses : systematic review " .
38-1	3389-3390	"	_	_	_	_
38-2	3391-3399	Physical	event[226]	new[226]	_	_
38-3	3400-3413	interventions	event[226]	new[226]	_	_
38-4	3414-3416	to	event[226]	new[226]	_	_
38-5	3417-3426	interrupt	event[226]	new[226]	_	_
38-6	3427-3429	or	event[226]	new[226]	_	_
38-7	3430-3436	reduce	event[226]	new[226]	_	_
38-8	3437-3440	the	event[226]|abstract[227]	new[226]|new[227]	appos	38-14[229_227]
38-9	3441-3447	spread	event[226]|abstract[227]	new[226]|new[227]	_	_
38-10	3448-3450	of	event[226]|abstract[227]	new[226]|new[227]	_	_
38-11	3451-3462	respiratory	event[226]|abstract[227]|abstract[228]	new[226]|new[227]|new[228]	_	_
38-12	3463-3470	viruses	event[226]|abstract[227]|abstract[228]	new[226]|new[227]|new[228]	_	_
38-13	3471-3472	:	_	_	_	_
38-14	3473-3483	systematic	abstract[229]	giv[229]	_	_
38-15	3484-3490	review	abstract[229]	giv[229]	_	_
38-16	3491-3492	"	_	_	_	_
38-17	3493-3494	.	_	_	_	_

#Text=BMJ . 339 ( sep21 1 ) : b3675 – b3675 .
39-1	3495-3498	BMJ	abstract[230]	new[230]	_	_
39-2	3499-3500	.	abstract[230]	new[230]	_	_
39-3	3501-3504	339	abstract[230]	new[230]	_	_
39-4	3505-3506	(	abstract[230]	new[230]	_	_
39-5	3507-3512	sep21	abstract[230]	new[230]	_	_
39-6	3513-3514	1	abstract[230]	new[230]	_	_
39-7	3515-3516	)	abstract[230]	new[230]	_	_
39-8	3517-3518	:	abstract[230]	new[230]	_	_
39-9	3519-3524	b3675	abstract[230]	new[230]	_	_
39-10	3525-3526	–	abstract[230]	new[230]	_	_
39-11	3527-3532	b3675	abstract[230]|abstract	new[230]|new	_	_
39-12	3533-3534	.	_	_	_	_

#Text=doi : 10.1136/bmj . b3675 .
40-1	3535-3538	doi	abstract[232]	giv[232]	coref	45-1[258_232]
40-2	3539-3540	:	abstract[232]	giv[232]	_	_
40-3	3541-3552	10.1136/bmj	abstract[232]	giv[232]	_	_
40-4	3553-3554	.	abstract[232]	giv[232]	_	_
40-5	3555-3560	b3675	abstract[232]	giv[232]	_	_
40-6	3561-3562	.	_	_	_	_

#Text=PMC 2190272 .
41-1	3563-3566	PMC	organization[233]	new[233]	_	_
41-2	3567-3574	2190272	organization[233]	new[233]	_	_
41-3	3575-3576	.	_	_	_	_

#Text=Chan , An-Wen ; Song , Fujian ; Vickers , Andrew ; Jefferson , Tom ; Dickersin , Kay ; Gøtzsche , Peter C ; Krumholz , Harlan M ; Ghersi , Davina ; van der Worp , H Bart ( January 2014 ) .
42-1	3577-3581	Chan	person[234]	new[234]	_	_
42-2	3582-3583	,	person[234]	new[234]	_	_
42-3	3584-3590	An-Wen	person[234]	new[234]	_	_
42-4	3591-3592	;	_	_	_	_
42-5	3593-3597	Song	person[235]	new[235]	_	_
42-6	3598-3599	,	person[235]	new[235]	_	_
42-7	3600-3606	Fujian	person[235]|person	new[235]|new	_	_
42-8	3607-3608	;	_	_	_	_
42-9	3609-3616	Vickers	person[237]	new[237]	_	_
42-10	3617-3618	,	person[237]	new[237]	_	_
42-11	3619-3625	Andrew	person[237]|person	new[237]|new	_	_
42-12	3626-3627	;	_	_	_	_
42-13	3628-3637	Jefferson	person[239]	giv[239]	coref	48-5[263_239]
42-14	3638-3639	,	person[239]	giv[239]	_	_
42-15	3640-3643	Tom	person[239]	giv[239]	_	_
42-16	3644-3645	;	_	_	_	_
42-17	3646-3655	Dickersin	person[240]	new[240]	_	_
42-18	3656-3657	,	person[240]	new[240]	_	_
42-19	3658-3661	Kay	person[240]|person	new[240]|new	_	_
42-20	3662-3663	;	_	_	_	_
42-21	3664-3672	Gøtzsche	person	new	appos	42-23[243_0]
42-22	3673-3674	,	_	_	_	_
42-23	3675-3680	Peter	person[243]	giv[243]	_	_
42-24	3681-3682	C	person[243]	giv[243]	_	_
42-25	3683-3684	;	_	_	_	_
42-26	3685-3693	Krumholz	person	new	appos	42-28
42-27	3694-3695	,	_	_	_	_
42-28	3696-3702	Harlan	person	giv	_	_
42-29	3703-3704	M	_	_	_	_
42-30	3705-3706	;	_	_	_	_
42-31	3707-3713	Ghersi	person[246]	new[246]	_	_
42-32	3714-3715	,	person[246]	new[246]	_	_
42-33	3716-3722	Davina	person[246]|person	new[246]|new	_	_
42-34	3723-3724	;	person[246]	new[246]	_	_
42-35	3725-3728	van	person[246]|object[248]	new[246]|giv[248]	_	_
42-36	3729-3732	der	person[246]|object[248]	new[246]|giv[248]	_	_
42-37	3733-3737	Worp	person[246]|object[248]	new[246]|giv[248]	_	_
42-38	3738-3739	,	person[246]|object[248]	new[246]|giv[248]	_	_
42-39	3740-3741	H	person[246]|object[248]|person	new[246]|giv[248]|new	_	_
42-40	3742-3746	Bart	person[246]|object[248]	new[246]|giv[248]	_	_
42-41	3747-3748	(	person[246]	new[246]	_	_
42-42	3749-3756	January	person[246]|time[250]	new[246]|new[250]	_	_
42-43	3757-3761	2014	person[246]|time[250]|time	new[246]|new[250]|new	_	_
42-44	3762-3763	)	person[246]	new[246]	_	_
42-45	3764-3765	.	_	_	_	_

#Text=" Increasing value and reducing waste : addressing inaccessible research " .
43-1	3766-3767	"	_	_	_	_
43-2	3768-3778	Increasing	_	_	_	_
43-3	3779-3784	value	abstract	new	_	_
43-4	3785-3788	and	_	_	_	_
43-5	3789-3797	reducing	_	_	_	_
43-6	3798-3803	waste	abstract	new	_	_
43-7	3804-3805	:	_	_	_	_
43-8	3806-3816	addressing	_	_	_	_
43-9	3817-3829	inaccessible	abstract[254]	new[254]	_	_
43-10	3830-3838	research	abstract[254]	new[254]	_	_
43-11	3839-3840	"	_	_	_	_
43-12	3841-3842	.	_	_	_	_

#Text=The Lancet . 383 ( 9913 ) : 257 – 266 .
44-1	3843-3846	The	organization[255]	new[255]	_	_
44-2	3847-3853	Lancet	organization[255]	new[255]	_	_
44-3	3854-3855	.	organization[255]	new[255]	_	_
44-4	3856-3859	383	organization[255]	new[255]	_	_
44-5	3860-3861	(	organization[255]	new[255]	_	_
44-6	3862-3866	9913	organization[255]|abstract	new[255]|new	_	_
44-7	3867-3868	)	organization[255]	new[255]	_	_
44-8	3869-3870	:	organization[255]	new[255]	_	_
44-9	3871-3874	257	organization[255]	new[255]	_	_
44-10	3875-3876	–	organization[255]	new[255]	_	_
44-11	3877-3880	266	organization[255]|abstract	new[255]|new	_	_
44-12	3881-3882	.	_	_	_	_

#Text=doi : 10.1016/S0140-6736(13)62296-5 .
45-1	3883-3886	doi	abstract[258]	giv[258]	coref	51-1[272_258]
45-2	3887-3888	:	abstract[258]	giv[258]	_	_
45-3	3889-3918	10.1016/S0140-6736(13)62296-5	abstract[258]	giv[258]	_	_
45-4	3919-3920	.	_	_	_	_

#Text=PMC 4533904 .
46-1	3921-3924	PMC	organization[259]	new[259]	_	_
46-2	3925-3932	4533904	organization[259]	new[259]	_	_
46-3	3933-3934	.	_	_	_	_

#Text=PMID 24411650 .
47-1	3935-3939	PMID	place[260]	new[260]	_	_
47-2	3940-3948	24411650	place[260]	new[260]	_	_
47-3	3949-3950	.	_	_	_	_

#Text=Doshi , P. ; Jefferson , T. ( 2 March 2015 ) .
48-1	3951-3956	Doshi	person[261]|person[262]	new[261]|new[262]	_	_
48-2	3957-3958	,	person[261]|person[262]	new[261]|new[262]	_	_
48-3	3959-3961	P.	person[261]|person[262]	new[261]|new[262]	_	_
48-4	3962-3963	;	person[262]	new[262]	_	_
48-5	3964-3973	Jefferson	person[262]|person[263]	new[262]|giv[263]	_	_
48-6	3974-3975	,	person[262]|person[263]	new[262]|giv[263]	_	_
48-7	3976-3978	T.	person[262]|person[263]|person	new[262]|giv[263]|new	_	_
48-8	3979-3980	(	person[262]|person[263]	new[262]|giv[263]	_	_
48-9	3981-3982	2	person[262]|person[263]	new[262]|giv[263]	_	_
48-10	3983-3988	March	person[262]|person[263]|time	new[262]|giv[263]|new	_	_
48-11	3989-3993	2015	person[262]|person[263]|time	new[262]|giv[263]|new	_	_
48-12	3994-3995	)	person[262]|person[263]	new[262]|giv[263]	_	_
48-13	3996-3997	.	_	_	_	_

#Text=" The evidence base for new drugs " .
49-1	3998-3999	"	_	_	_	_
49-2	4000-4003	The	abstract[268]	new[268]	_	_
49-3	4004-4012	evidence	abstract|abstract[268]	new|new[268]	_	_
49-4	4013-4017	base	abstract[268]	new[268]	_	_
49-5	4018-4021	for	abstract[268]	new[268]	_	_
49-6	4022-4025	new	abstract[268]|substance[269]	new[268]|new[269]	_	_
49-7	4026-4031	drugs	abstract[268]|substance[269]	new[268]|new[269]	_	_
49-8	4032-4033	"	_	_	_	_
49-9	4034-4035	.	_	_	_	_

#Text=BMJ . 350 ( mar02 6 ) : h952 – h952 .
50-1	4036-4039	BMJ	abstract[270]	new[270]	_	_
50-2	4040-4041	.	abstract[270]	new[270]	_	_
50-3	4042-4045	350	abstract[270]	new[270]	_	_
50-4	4046-4047	(	abstract[270]	new[270]	_	_
50-5	4048-4053	mar02	abstract[270]	new[270]	_	_
50-6	4054-4055	6	abstract[270]	new[270]	_	_
50-7	4056-4057	)	abstract[270]	new[270]	_	_
50-8	4058-4059	:	abstract[270]	new[270]	_	_
50-9	4060-4064	h952	abstract[270]	new[270]	_	_
50-10	4065-4066	–	abstract[270]	new[270]	_	_
50-11	4067-4071	h952	abstract[270]|abstract	new[270]|new	_	_
50-12	4072-4073	.	_	_	_	_

#Text=doi : 10.1136/bmj . h952 .
51-1	4074-4077	doi	abstract[272]	giv[272]	_	_
51-2	4078-4079	:	abstract[272]	giv[272]	_	_
51-3	4080-4091	10.1136/bmj	abstract[272]	giv[272]	_	_
51-4	4092-4093	.	abstract[272]	giv[272]	_	_
51-5	4094-4098	h952	abstract[272]	giv[272]	_	_
51-6	4099-4100	.	_	_	_	_
